Lucy Gilbert

10.1k total citations · 2 hit papers
160 papers, 3.5k citations indexed

About

Lucy Gilbert is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Oncology. According to data from OpenAlex, Lucy Gilbert has authored 160 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Reproductive Medicine, 58 papers in Obstetrics and Gynecology and 52 papers in Oncology. Recurrent topics in Lucy Gilbert's work include Ovarian cancer diagnosis and treatment (67 papers), Endometrial and Cervical Cancer Treatments (55 papers) and Cancer Genomics and Diagnostics (25 papers). Lucy Gilbert is often cited by papers focused on Ovarian cancer diagnosis and treatment (67 papers), Endometrial and Cervical Cancer Treatments (55 papers) and Cancer Genomics and Diagnostics (25 papers). Lucy Gilbert collaborates with scholars based in Canada, United States and United Kingdom. Lucy Gilbert's co-authors include Jack Y.J. Huang, Seang Lin Tan, Ri‐Cheng Chian, William Buckett, David M. O’Malley, Ana Oaknin, Hananel Holzer, Kathleen N. Moore, G. Stanimir and Diane Provencher and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Lucy Gilbert

147 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

2020 237 citations Ana Oaknin, Anna V. Tinker et al. profile →
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

2023 81 citations Lucy Gilbert, Ana Oaknin et al. Gynecologic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lucy Gilbert Canada	29	1.4k	1.1k	740	570	568	160	3.5k
Annette Hasenburg Germany	38	1.1k 0.8×	2.3k 2.1×	805 1.1×	251 0.4×	886 1.6×	260	4.9k
Andy Ryan United Kingdom	29	910 0.6×	712 0.7×	523 0.7×	143 0.3×	1.2k 2.0×	99	3.0k
Walter H. Gotlieb Canada	42	2.5k 1.7×	1.6k 1.4×	2.3k 3.1×	458 0.8×	1.7k 3.1×	244	6.4k
G. Larry Maxwell United States	37	2.3k 1.6×	977 0.9×	1.8k 2.5×	222 0.4×	1.4k 2.5×	168	4.9k
Peter A. Argenta United States	33	1.4k 1.0×	1.1k 1.0×	1000 1.4×	118 0.2×	669 1.2×	99	3.7k
Sang‐Yoon Park South Korea	34	1.3k 0.9×	810 0.7×	1.2k 1.7×	155 0.3×	906 1.6×	197	3.7k
Jianliu Wang China	30	621 0.4×	543 0.5×	886 1.2×	233 0.4×	1.0k 1.8×	319	3.4k
Anna Myriam Perrone Italy	26	912 0.6×	346 0.3×	947 1.3×	161 0.3×	429 0.8×	165	2.4k
Sun Lee United States	29	327 0.2×	643 0.6×	484 0.7×	194 0.3×	467 0.8×	160	3.2k
Kimio Ushijima Japan	28	1.4k 1.0×	850 0.8×	1.2k 1.7×	142 0.2×	756 1.3×	159	3.2k

Countries citing papers authored by Lucy Gilbert

Since Specialization

Citations

This map shows the geographic impact of Lucy Gilbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucy Gilbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucy Gilbert more than expected).

Fields of papers citing papers by Lucy Gilbert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lucy Gilbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucy Gilbert. The network helps show where Lucy Gilbert may publish in the future.

Co-authorship network of co-authors of Lucy Gilbert

This figure shows the co-authorship network connecting the top 25 collaborators of Lucy Gilbert. A scholar is included among the top collaborators of Lucy Gilbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucy Gilbert. Lucy Gilbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lindemann, Kristina, Zhongqiu Lin, Shin Nishio, et al.. (2025). TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer. International Journal of Gynecological Cancer. 35(2). 100497–100497. 1 indexed citations

Miller, Robert F., Jubilee Brown, JW Kim, et al.. (2025). 69O Novel regimens for persistent/recurrent rare epithelial ovarian carcinomas (EOCs) selected according to biomarker status: ENGOT-GYN2/GOG-3051/BOUQUET phase II study results. ESMO Open. 10. 105199–105199.

Tessier‐Cloutier, Basile, et al.. (2025). The challenge of managing isolated STIC lesions: A single-center experience. Gynecologic Oncology Reports. 58. 101716–101716.

Vaishampayan, Ulka N., Jameel Muzaffar, Ira Winer, et al.. (2024). Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1). Journal for ImmunoTherapy of Cancer. 12(11). e010143–e010143. 14 indexed citations

Jørgensen, Trine Lembrecht, Destin Black, David Cibula, et al.. (2024). Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.. Journal of Clinical Oncology. 42(16_suppl). 5607–5607. 1 indexed citations

McCormack, Mary, Yong‐Man Kim, Sharad Ghamande, et al.. (2024). A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). International Journal of Gynecological Cancer. 34(8). 1140–1148. 16 indexed citations

Pignata, Sandro, Mariusz Bidziński, M.J. Rubio Pérez, et al.. (2024). 39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer. ESMO Open. 9. 103539–103539. 2 indexed citations

Marth, Christian, Richard D. Moore, Mariusz Bidziński, et al.. (2024). Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study. Gynecologic Oncology. 190. S63–S64.

Ghamande, Sharad, Lars Hanker, Destin Black, et al.. (2024). Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Gynecologic Oncology. 190. S6–S6. 11 indexed citations

10.

Mirza, Mansoor Raza, Sudarshan Sharma, Jørn Herrstedt, et al.. (2023). 740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Annals of Oncology. 34. S507–S507. 20 indexed citations

11.

Chase, Dana M., Line Bjørge, Robert L. Coleman, et al.. (2023). #267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial. A8–A9. 2 indexed citations

12.

Slomovitz, Brian M., Robert L. Coleman, Lucy Gilbert, et al.. (2023). 750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial. Annals of Oncology. 34. S514–S515. 2 indexed citations

13.

Mirza, Mansoor Raza, Dana M. Chase, Brian M. Slomovitz, et al.. (2023). Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11). Gynecologic Oncology. 176. S43–S44. 2 indexed citations

14.

Moore, Kathleen N., Antoine Angelergues, Gottfried E. Konecny, et al.. (2023). Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.. Journal of Clinical Oncology. 41(17_suppl). LBA5507–LBA5507. 37 indexed citations

15.

Oaknin, Ana, Lucy Gilbert, Anna V. Tinker, et al.. (2023). A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer. Future Oncology. 19(25). 1709–1714. 1 indexed citations

16.

Tinker, Anna V., Renaud Sabatier, Adriano Gravina, et al.. (2022). 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. International Journal of Gynecological Cancer. 32. A414–A414. 5 indexed citations

17.

Gilbert, Lucy, Agnihotram V. Ramanakumar, К. Jardon, et al.. (2020). Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy. Journal of Comparative Effectiveness Research. 9(8). 537–551. 4 indexed citations

18.

El‐Zein, Mariam, Walter H. Gotlieb, Lucy Gilbert, et al.. (2020). Dual staining for p16/Ki‐67 to detect high‐grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study. International Journal of Cancer. 148(2). 492–501. 15 indexed citations

19.

El‐Zein, Mariam, Karolina Louvanto, Lucy Gilbert, et al.. (2019). Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions. Cancer Epidemiology Biomarkers & Prevention. 28(7). 1134–1140. 22 indexed citations

20.

Naumann, R. Wendel, Robert L. Coleman, Robert A. Burger, et al.. (2013). PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology. 31(35). 4400–4406. 169 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact